Moderna, Inc. (NASDAQ:MRNA) CEO Sells $6,034,800.00 in Stock

Moderna, Inc. (NASDAQ:MRNA – Get Rating) CEO Stephane Bancel sold 40,000 shares of the business’s stock in a transaction dated Thursday, March 16th. The stock was sold at an average price of $150.87, for a total transaction of $6,034,800.00. Following the sale, the chief executive officer now directly owns 5,411,946 shares in the company, valued at $816,500,293.02. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Stephane Bancel also recently made the following trade(s):

• On Thursday, March 9th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $139.20, for a total transaction of $5,568,000.00.
• On Thursday, March 2nd, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $137.50, for a total transaction of $5,500,000.00.
• On Thursday, February 16th, Stephane Bancel sold 40,000 shares of Moderna stock. The stock was sold at an average price of $173.07, for a total transaction of $6,922,800.00.
• On Wednesday, February 8th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $166.00, for a total transaction of $6,640,000.00.
• On Thursday, January 26th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $190.67, for a total transaction of $7,626,800.00.
• On Thursday, January 19th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $192.06, for a total transaction of $7,682,400.00.
• On Wednesday, January 11th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $185.02, for a total transaction of $7,400,800.00.
• On Wednesday, January 4th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $178.11, for a total transaction of $7,124,400.00.
• On Thursday, December 29th, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $179.85, for a total transaction of $7,194,000.00.
• On Thursday, December 22nd, Stephane Bancel sold 40,000 shares of Moderna stock. The shares were sold at an average price of $205.31, for a total transaction of $8,212,400.00.

Moderna Stock Performance

NASDAQ MRNA opened at $150.02 on Friday. The company has a current ratio of 2.73, a quick ratio of 2.54 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $57.86 billion, a price-to-earnings ratio of 7.52 and a beta of 1.70. The firm’s 50 day simple moving average is $167.52 and its 200 day simple moving average is $160.53. Moderna, Inc. has a 1 year low of $115.03 and a 1 year high of $217.25.

Moderna (NASDAQ:MRNA – Get Rating) last posted its quarterly earnings results on Thursday, February 23rd. The company reported $3.61 EPS for the quarter, missing analysts’ consensus estimates of $4.66 by ($1.05). The business had revenue of $5.08 billion for the quarter, compared to analyst estimates of $5.02 billion. Moderna had a return on equity of 46.34% and a net margin of 43.41%. Moderna’s quarterly revenue was down 29.5% on a year-over-year basis. During the same period last year, the firm posted $11.29 EPS. As a group, research analysts expect that Moderna, Inc. will post -2.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Ronald Blue Trust Inc. increased its position in Moderna by 307.4% during the 4th quarter. Ronald Blue Trust Inc. now owns 220 shares of the company’s stock worth $26,000 after purchasing an additional 166 shares in the last quarter. Roble Belko & Company Inc acquired a new position in shares of Moderna during the fourth quarter worth $27,000. ICA Group Wealth Management LLC bought a new position in shares of Moderna in the 4th quarter valued at $27,000. Evoke Wealth LLC boosted its holdings in shares of Moderna by 100.8% during the 3rd quarter. Evoke Wealth LLC now owns 239 shares of the company’s stock valued at $28,000 after acquiring an additional 120 shares in the last quarter. Finally, Guardian Wealth Advisors LLC bought a new stake in Moderna during the 3rd quarter worth $28,000. Institutional investors own 63.11% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on MRNA. Piper Sandler increased their price target on shares of Moderna from $214.00 to $217.00 and gave the company an “overweight” rating in a report on Tuesday, December 20th. Cowen increased their price target on shares of Moderna from $130.00 to $150.00 and gave the company a “market perform” rating in a report on Wednesday, January 25th. Royal Bank of Canada began coverage on shares of Moderna in a report on Wednesday, March 1st. They issued an “outperform” rating and a $200.00 price target on the stock. SVB Securities cut shares of Moderna from a “market perform” rating to an “underperform” rating and lowered their price target for the company from $111.00 to $93.00 in a report on Friday, February 24th. Finally, Jefferies Financial Group raised shares of Moderna from a “hold” rating to a “buy” rating and increased their price target for the company from $170.00 to $275.00 in a report on Monday, December 19th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Moderna presently has an average rating of “Hold” and a consensus price target of $180.80.

About Moderna

(Get Rating)

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.